MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
March 08, 2023 17:36 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
November 17, 2022 18:10 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
PRVB BREAKING ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – PRVB
June 04, 2021 19:15 ET
|
The Rosen Law Firm PA
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2,...